Pavla Taborska

Pavla Taborska

Auto-generated profile, based on publicly available information

Pavla Taborska

Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic, cuni.cz

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KKKaterina Kalkusova
Katerina Kalkusova
PTPavla Taborska
Pavla Taborska
DSDmitry Stakheev
Dmitry Stakheev
DSDaniel Smrz
Daniel Smrz
MicroRNAs belong to a group of short non-coding RNA molecules that are involved in the regulation of gene expression at multiple levels. Their function was described two decades ago, and, since then, microRNAs have become a rapidly developing field of research. Their participation in the regulation of cellular processes, such as proliferation, apoptosis, cell growth, and migration, made microRNAs attractive for cancer research. Moreover, as a single microRNA can simultaneously target multiple molecules, microRNAs offer a unique advantage in regulating multiple cellular processes in different cell types. Many of these cell types are tumor cells and the cells of the immune system. One of the most studied microRNAs in the context of cancer and the immune system is miR-155. MiR-155 plays a role in modulating innate and adaptive immune mechanisms in distinct immune cell types. As such, miR-155 can be part of the communication between the tumor and immune cells and thus impact the process of tumor immunoediting. Several studies have already revealed its effect on antitumor immune responses, and the targeting of this molecule is increasingly implemented in cancer immunotherapy. In this review, we discuss the current knowledge of miR-155 in the regulation of antitumor immunity and the shaping of the tumor microenvironment, and the plausible implementation of miR-155 targeting in cancer therapy.

18 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DSDmitry Stakheev
Dmitry Stakheev
PTPavla Taborska
Pavla Taborska
Zuzana StrizovaZuzana Strizova
Zuzana Strizova
MPMichal Podrazil
Michal Podrazil
JBJirina Bartunkova
Jirina Bartunkova
DSDaniel Smrz
Daniel Smrz
Upregulated Wnt/β-catenin signaling is associated with increased cancer cell resistance and cancer cell-elicited immunosuppression. In non-neoplastic immune cells, upregulated Wnt/β-catenin is, however, associated with either immunosuppression or immunostimulation. Therefore, it is difficult to predict the therapeutic impact inhibitors of Wnt/β-catenin signaling will have when combined with cancer immunotherapy. Here, we evaluated the benefit(s) of the Wnt/β-catenin signaling inhibitor XAV939 in the in vitro elimination of LNCaP prostate cancer cells when cocultured with lymphocytes from patients with localized biochemically recurrent prostate cancer (BRPCa). We found that 5 µM XAV939 inhibited β-catenin translocation to the nucleus in LNCaP cells and CD4+ BRPCa lymphocytes without affecting their proliferation and viability. Preconditioning BRPCa lymphocytes with 5 µM XAV939 accelerated the elimination of LNCaP cells during the coculturing. However, during subsequent re-coculturing with fresh LNCaP cells, BRPCa lymphocytes were no longer able to eliminate LNCaP cells unless coculturing and re-coculturing were performed in the presence of 5 µM XAV939. Comparable results were obtained for PC-3 prostate cancer cells. These findings provide a rationale for combining cell-based immunotherapy of PCa with inhibitors of Wnt/β-catenin signaling.

1 July 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
Zuzana StrizovaZuzana Strizova
Zuzana Strizova
PTPavla Taborska
Pavla Taborska
DSDmitry Stakheev
Dmitry Stakheev
SPSimona Partlová
Simona Partlová
KHKlara Havlova
Klara Havlova
DSDaniel Smrz
Daniel Smrz

1 July 2018 in Journal of Immunological Methods
Verified
Journal Article
Closed access
PTPavla Taborska
Pavla Taborska
JBJirina Bartunkova
Jirina Bartunkova
DSDaniel Smrz
Daniel Smrz

23 May 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Zuzana StrizovaZuzana Strizova
Zuzana Strizova
MSMartin Snajdauf
Martin Snajdauf
DSDmitry Stakheev
Dmitry Stakheev
PTPavla Taborska
Pavla Taborska
JVJiri Vachtenheim
Jiri Vachtenheim
DSDaniel Smrz
Daniel Smrz

Verified
Journal Article
Open access
PDF file
KKKaterina Kalkusova
Katerina Kalkusova
SSSindija Smite
Sindija Smite
EDElea Darras
Elea Darras
PTPavla Taborska
Pavla Taborska
DSDmitry Stakheev
Dmitry Stakheev
DSDaniel Smrz
Daniel Smrz
The immune checkpoint inhibitors have revolutionized cancer immunotherapy. These inhibitors are game changers in many cancers and for many patients, sometimes show unprecedented therapeutic efficacy. However, their therapeutic efficacy is largely limited in many solid tumors where the tumor-controlled immune microenvironment prevents the immune system from efficiently reaching, recognizing, and eliminating cancer cells. The tumor immune microenvironment is largely orchestrated by immune cells through which tumors gain resistance against the immune system. Among these cells are mast cells and dendritic cells. Both cell types possess enormous capabilities to shape the immune microenvironment. These capabilities stage these cells as cellular checkpoints in the immune microenvironment. Regaining control over these cells in the tumor microenvironment can open new avenues for breaking the resistance of solid tumors to immunotherapy. In this review, we will discuss mast cells and dendritic cells in the context of solid tumors and how these immune cells can, alone or in cooperation, modulate the solid tumor resistance to the immune system. We will also discuss how this modulation could be used in novel immunotherapeutic modalities to weaken the solid tumor resistance to the immune system. This weakening could then help other immunotherapeutic modalities engage against these tumors more efficiently.